KPV 10 mg— Research Protocol

Quickstart Highlights

KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects^[1][2]. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation^[3].

Storage Instructions

Proper storage preserves peptide quality and stability.

• Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light^[6][7].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days^[7].
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid freeze–thaw cycles: Do not refreeze reconstituted peptide solutions; prepare aliquots if long‑term storage is needed^[6].

How It Works

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects^[1][2]. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation^[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release^[2]. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols^[4].

Potential Benefits & Side Effects

Observations from preclinical and early‑stage research.

• Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation^[3].
• Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability^[4].
• Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation^[5].
• Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
• No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation^[1].

References

• Journal of Pharmaceutical Drug Delivery Research (2022)Pawar K. et al.: KPV as an α‑MSH fragment retains potent anti‑inflammatory activity without melanotropic side effects
  
  
• Gastroenterology (2008)Dalmasso G. et al.: PepT1‑mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis models
• Innerbody Research (2025)KPV peptide benefits, safety, and administration routes; subcutaneous injection for systemic therapy
• Peptides.org Dosage Guide (2023)KPV dosage calculator and protocol: 200–400 mcg subcutaneously once daily for inflammation and wound healing
• Bachem (Peptide Handling Guidelines)Long‑term peptide stability best achieved in lyophilized form at <−15 °C; avoid extended storage in solution
• PeptideSciences (Storage Guidelines)Lyophilized peptides stable for short‑term at 4 °C, long‑term at −20 °C; reconstituted solutions refrigerated up to ~30 days
• Johns Hopkins Arthritis CenterSubcutaneous injection technique: site preparation, needle angle (45–90°), and injection site rotation
• NCBI Bookshelf (Clinical Procedures)Best practices for injection: aseptic technique, site preparation, and administration procedures
• CDC Vaccine AdministrationSubcutaneous injection route guidance: needle angle, site selection, and no aspiration for subcut injections
• PMC (Subcutaneous Drug Injection Review)Pharmacologic and physiologic considerations of the subcutaneous route for drug administration